The healthcare product giant Abbott Laboratories (NYSE:ABT) has recently reported that the company has been honored with Conformité Européenne (CE) Marking in Europe for the FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System™.
According to the report, the icon-driven device is featured with sleek design which offers visual glucose trend indicators along with insulin logging support for daily diabetes management. Further, FreeStyle Optium Neo System offers assistance to healthcare professionals with its insulin dose feature which organizes a patient’s insulin plan into the meter. Also, the meter provides the user with actual insulin log doses which can be navigated move up or down arrows.
As per the global health body World Health Organization, has mentioned in its August 2013 report that the occurrence of diabetes is rising in the European region. The report also states that in Europe, nearly 10% of women and men within the age of 25 years and older are suffering with diabetes, making diabetes as one of the major widespread chronic health hazard.
As per the company, FreeStyle Optium Neo System will be released shortly over Europe in coming weeks.
The company’s Senior Vice President, Diabetes Care, commented, “The FreeStyle Optium Neo System is our latest advance based on the innovative technology that is at the heart of both our Precision and Optium products. It combines powerful features, ease-of-use and the ability to analyze important glucose trends in a single device. The device’s advanced design and technology enables the ability to track glucose trends and log insulin, which may help improve the patient’s daily diabetes management. This system is one more example of how Abbott is focused on meeting the needs of patients.”
Moving on, the company has stated that it won to manage public affairs and PR activities of Weber Shandwick over Asia and Europe. However, the fee negotiations are still in progress with a possibility of expansion and a probability of covering the Latin America region as well